A practical reference on human growth hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-07-24. Anything still debated is marked as such rather than presented as settled.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
=== Mutation === A locus at 14q has been suggested, but no gene has been identified. A second locus has been identified on chromosome 8 and a third has been reported on chromosome 2. This suggests there may be some genetic heterogeneity in this disease. A mutation in the gene encoding the type III sodium dependent phosphate transporter 2 (SLC20A2) located on chromosome 8 has been reported. Biochemical evidence suggests that phosphate transport may be involved in this disease. Two other genes have been associated with this condition: PDGFB on chromosome 22 and PDGFRB on chromosome 5. These genes are biochemically linked: PDGFRB encodes the platelet-derived growth factor receptor β and PDGFB encodes the ligand of PDGF-Rβ. These genes are active during angiogenesis to recruit pericytes which suggests that alterations in the blood brain barrier may be involved in the pathogenesis of this condition. A fourth gene associated with this condition is XPR1. This gene is the long arm of located on chromosome 1 (1q25.3). Another gene that has been associated with this condition is MYORG. This gene is located on the long arm of chromosome 9 (9p13.3). This gene is associated with an autosomal recessive inheritance pattern in this condition. Another gene junctional adhesion molecule 2 (JAM2) has been associated with an autosomal recessive form of this condition. The most recently found gene to be associated with PFBC is Nα-acetyltransferase 60 (NAA60).
== Awards and honours == 2011 American Chemical Society Cincinnati Chemist of the Year 2015 American Microchemical Society Benedetti Pichler Award 2016 Power List of Top 50 Women Analytical Scientists 2016 Fellow of the Royal Society of Chemistry 2021 The Chromatography Forum of the Delaware Valley Stephen Dal Nogare Award
Adipose tissue (also known as body fat or simply fat) is a loose connective tissue composed mostly of adipocytes. It also contains the stromal vascular fraction of cells including preadipocytes, fibroblasts, vascular endothelial cells and a variety of immune cells such as adipose tissue macrophages. Its main role is to store energy in the form of lipids, although it also cushions and insulates the body. Previously treated as being hormonally inert, in recent years adipose tissue has been recognized as a major endocrine organ, as it produces hormones such as leptin, estrogen, resistin, and cytokines (especially TNFα). In obesity, adipose tissue is implicated in the chronic release of pro-inflammatory markers known as adipokines, which are responsible for the development of metabolic syndrome—a constellation of diseases including type 2 diabetes, cardiovascular disease and atherosclerosis. Adipose tissue is derived from preadipocytes and its formation appears to be controlled in part by the adipose gene. The two types of adipose tissue are white adipose tissue (WAT), which stores energy, and brown adipose tissue (BAT), which generates body heat. Adipose tissue—more specifically brown adipose tissue—was first identified by the Swiss naturalist Conrad Gessner in 1551.
=== Capillary electrophoresis === One significant advancement in the field is the development of integrated capillary electrophoresis (CE) systems on microchips, as demonstrated by Z. Hugh Fan and D. Jed. Harrison. They created a planar glass chip incorporating a sample injector and separation channels using micromachining techniques. This setup allowed for the rapid separation of amino acids in just a few seconds, achieving high separation efficiencies with up to 6800 theoretical plates. The use of high electric fields, possible due to the thermal mass and conductivity of glass, minimized Joule heating effects, making the system highly efficient and fast. Such innovations highlight the potential of microfluidic devices in analytical chemistry, particularly in applications requiring quick and precise analyses.
=== 2013–2015: Emergence as a half-back flanker === The 2013 season saw Hibberd play every match of the year for the first time in his career. His performances during the season was described by The Age journalist, Rohan Connolly, as "the best football of his career" and he was named in Connolly's mid-season All-Australian team. His running off of half-back saw him compared to six time All-Australian, Corey Enright, by Rohan Connolly. After the announcement of the forty man squad for the 2013 All-Australian team, he was considered unlucky to miss out on selection by AFL Media journalist, Nick Bowen, and The Age journalist and former player, Matthew Lloyd. His improved season saw him finish fourth in the clubs best and fairest count. Despite a hamstring injury during the 2014 NAB Challenge, Hibberd played the first fourteen matches of the year, before he was forced to miss the round sixteen match against Port Adelaide at the Adelaide Oval due to an ankle injury. He returned to the side two weeks later for the seven point win against the Western Bulldogs at Etihad Stadium in round eighteen, before succumbing to a hamstring injury the next week and missed two weeks. He returned from injury in the three point win against West Coast at Etihad Stadium in round twenty-one, where he was named the best player for Essendon by The Age and AFL Media. He played the remainder of the season, including his first final in the twelve point loss against North Melbourne at the Melbourne Cricket Ground in the second elimination final.
Sources: en.wikipedia.org
== History == Interchim was founded by Boch Jean (formerly chemical engineer at Rhone-Poulenc) and Boch Colette in 1970. Their initial activity started with distribution of fine chemicals, then chromatography and Biology. Production was developed as well, in each fields. Affiliate companies were created for production and commercial activities in France, UK (2003), USA (2007) and Instrumentation business (2010). Interchim has now major activity in fine chromatography, fine chemistry and bio-analysis. Leadership in analytical sciences is based on distribution from leading groups (Agilent, Perkin Elmer, Jackson Immunoresearch, Novus, Radleys...), collaborations and proprietary innovative products.
=== Anhydrous structure === Anhydrous Dy(ClO4)3 crystallizes in the hexagonal crystal system, space group P63/m (No. 176). It is isostructural with the anhydrous perchlorates of La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Ho and Er, and belongs to a structure family related to the UCl3 type. In this structure the Dy3+ centres are nine-coordinate. The coordination environment is formed by oxygen atoms belonging to perchlorate groups, which act as multidentate ligands and generate a three-dimensional channel-containing framework. Across the lanthanide series, the lattice parameters decrease systematically because of the lanthanide contraction.
shorter needles, as insulin injections are subcutaneous (under the skin) rather than intramuscular, finer gauge needles, for less pain, markings in insulin units to simplify drawing a measured dose of insulin, and low dead space to reduce complications caused by improper drawing order of different insulin strengths.
== History == The concept of the regulation of the internal environment was described by French physiologist Claude Bernard in 1849, and the word homeostasis was coined by Walter Bradford Cannon in 1926. In 1932, Joseph Barcroft, a British physiologist, was the first to say that higher brain function required the most stable internal environment. Thus, to Barcroft homeostasis was not only organized by the brain—homeostasis served the brain. Homeostasis is an almost exclusively biological term, referring to the concepts described by Bernard and Cannon, concerning the constancy of the internal environment in which the cells of the body live and survive. The term cybernetics is applied to technological control systems such as thermostats, which function as homeostatic mechanisms but are often defined much more broadly than the biological term of homeostasis.
In May 2012, Starbucks opened its first coffeehouse in Finland, with the location being Helsinki-Vantaa Airport in Vantaa. In August 2013, the first Starbucks inside Dansk Supermarked opened in the department stores Salling in Aalborg and Aarhus in Denmark. In November 2014, Starbucks announced its first Channel Island store, in the primary business area of St Peter Port in Guernsey. On April 21, 2015, Kesko, the second largest retailer in Finland, announced its partnership with Starbucks, with stores opened next to K-Citymarket hypermarkets. As of June 2017, three stores had been opened next to K-Citymarkets: In Sello in Espoo and in Myyrmanni and Jumbo in Vantaa. In February 2016, Howard Schultz announced the opening of stores in Italy. The first Italian Starbucks store was inaugurated in Milan on September 6, 2018, at which point Starbucks already had locations in 78 countries. In May 2016, the first Starbucks store in Slovakia opened in Aupark, in Bratislava. In June 2018, Starbucks announced the opening of stores in Serbia. The first store was opened in April 2019 at Rajiceva Mall. On June 1, 2019, Starbucks opened its first coffee store in Valletta, Malta, the 80th country to have a Starbucks outlet. In July 2025, Starbucks opened its first store in Iceland.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.